KEAP1 and non-small cell lung carcinoma: Similarly, Ji and coworkers noted amplification by PCR in 42% of Chinese LUSC patients.20, 21Furthermore, a study conducted by Best et al elucidated the synergistic interplay between the KEAP1/NRF2 and PI3K pathways, which contributes to the development of NSCLC with an altered immune microenvironment.51The researchers observed that NRF2 exhibits oncogenic activity downstream of the PI3K pathway.